

August 10, 2024

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2024.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2024.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl.: As above

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com

Hyderabad, India, August 10th, 2024: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended June 30, 2024.

Aurobindo Pharma Ltd. Q1FY25 Consolidated Financial Results

Amount (INR Cr)	Q1FY25	Q1FY24	% Change YoY	Q4FY24	% Change QoQ
Revenue from Operations	7,567	6,851	10.5%	7,580	-0.2%
EBITDA before Forex and Other Income	1,620	1,151	40.7%	1,687	-4.0%
EBITDA Margin (%)	21.4%	16.8%	460 bps	22.3%	-85 bps
PBT before share of P/L of JV, Forex, and Exceptional items	1,324	847	56.4%	1,379	-4.0%
Net Profit after Share of Profit/Loss of JV and Minority Interest	919	571	61.1%	909	1.1%

Key Highlights of Q1FY25

- Revenue from Operations increased by 10.5% YoY to INR 7,567 Cr with growth across the businesses
- US formulations (excluding Puerto Rico) revenue increased by 13.3% YoY to INR 3,555 Cr (USD 426 million)
- Europe formulations revenue increased by 7.9% YoY to INR 1,982 Cr (EUR 221 million)
- Growth Markets revenue increased by 49.2% YoY to INR 709 Cr (USD 85 million)
- ARV revenue increased by 13.9% YoY to INR 229 Cr (USD 27 million)
- API revenue grew by 5.6% YoY to INR 1,092 Cr (USD 131 million)
- EBITDA before Forex and Other Income stood at INR 1,620 Cr; EBITDA margin at 21.4%
- Research & Development (R&D) spend was INR 339 Cr, 4.5% of revenues
- Received final approval for 10 ANDAs including 1 Specialty & Injectable product from the USFDA
- Net Profit after Share of Profit/Loss of JV and Minority Interest at INR 919 Cr, vs. INR 571 Cr in Q1FY24
- Basic & Diluted EPS grew by 61.4% YoY to INR 15.69 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments. Our profitability was sustained by improved gross margins and operational efficiencies, while ramping-up our recently commercialized plants. We are confident in our ability to achieve our growth targets for FY25."



Operational Performance (Consolidated)

₹ Cr	Q1FY25	Q1FY24	Y-o-Y (%)	Q4FY24	Q-o-Q (%)
USA	3,555	3,137	13.3%	3,588	-0.9%
Europe	1,982	1,837	7.9%	1,832	8.2%
Growth Markets	709	475	49.2%	852	-16.7%
ARV	229	201	13.9%	238	-4.0%
Total Formulations	6,475	5,650	14.6%	6,510	-0.5%
Beta-lactam	791	719	9.9%	698	13.3%
Non Beta-lactam	301	314	-4.1%	321	-6.1%
Total API	1,092	1,033	5.6%	1,019	7.2%
Consolidated Sales (Ex- Puerto Rico)	7,567	6,683	13.2%	7,529	0.5%
Puerto Rico	-	167	-	51	-
Revenue from operations	7,567	6,851	10.5%	7,580	-0.2%

*includes domestic formulation sales of INR 61 Cr in Q1FY25

Q1FY25: Consolidated Revenue Breakup - Geography & Business wise

Q1FY25



Q1FY25 Performance

Formulations revenue increased by 14.6% YoY to INR 6,475 Cr

US Formulations

- US revenue increased by 13.3% YoY to INR 3,555 Cr and accounted for 47.0% of consolidated revenue
- In USD terms, revenue increased by 11.6% YoY to USD 426 million
- Filed 8 ANDAs with USFDA during the quarter
- Received final approval for 10 ANDAs including 1 specialty product during the quarter
- As on 30th June 2024, on a cumulative basis, the company has filed 838 ANDAs with USFDA and received 668 final approvals and 26 tentative approvals
- The company has launched 10 products including 1 injectables during the quarter

Europe Formulations

- Europe revenue increased by 7.9% YoY to INR 1,982 Cr and accounted for 26.2% of consolidated revenue
- In Euro terms, revenue stood at EUR 221 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 49.2% YoY to INR 709 Cr and accounted for 9.4% of consolidated revenue
- In USD terms, revenue increased by 47.0% YoY to USD 85 million
- Domestic formulation sales in stood at INR 61 Cr

ARV Formulations

- ARV business revenue increased by 13.9% YoY to INR 229 Cr and accounted for 3.0% of consolidated revenue
- In USD terms, revenue increased by 12.1% YoY to USD 27 million

Active Pharmaceutical Ingredients (API)

- API business revenue increased by 5.6% to INR 1,092 Cr and contributed 14.4% of consolidated revenue
- In USD terms, revenue increased by 4.0% YoY to USD 131 million

Global Regulatory Filings

Details	Q1FY25	Cumulative Filings as on 30 th June 2024
US ANDAs (including filings from Aurobindo USA)	8	838
US DMFs (including filings from Eugia and Auro Peptides)	1	292
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	155	4,461
API filings in other key regulated markets (incl. multiple registrations)	47	3,835

Final USFDA Approvals Received in Q1 FY25

Received by Aurobindo Pharma Limited

#	Product	Strength	Therapy area
1	Colchicine Capsules	0.6 mg	Anti-Gout
2	Ibuprofen Oral Suspension USP (OTC)	50 mg/1.25 mL	Pain Relief Drugs
3	Fluticasone Propionate Nasal Spray USP (OTC)	50 mcg	Corticosteroids
4	Lidocaine Ointment USP	5%	CNS
5	Oseltamivir Phosphate for Oral Suspension	6 mg/mL	Anti-Infective
6	Betamethasone Dipropionate Ointment USP	0.05%	Glucocorticoid
7	Tofacitinib Extended-Release Tablets	11 mg	Pain Relief Drugs
8	Minoxidil Topical Aerosol (OTC)	5%	Hair Regrowth Stimulant
9	Haloperidol Tablets USP	0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg and 20 mg	CNS

Received by Eugia Pharma Specialities

#	Product	Strength	Therapy area
1	Busulfan Injection	60 mg/10 mL	Anti-Neoplastic Agent

Q1FY25 Earnings Call Details

The company will host earnings call at **8.30 AM IST on 12th August 2024**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <http://bit.ly/3LNq4fd>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 29 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com